Estudo randomizado | Eficácia do HD201 vs. trastuzumabe em pacientes com câncer de mama ERBB2-positivo em terapia neoadjuvante.

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant SettingA Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology

Comentário no Twitter

Trastuzumab dramatically improves outcome of HER2-positive breast cancer, though its high price limits access. HD201 is a biosimilar tested vs trastuzumab in HER2-positive early breast cancer, showing equivalence in pathologic complete response rates https://t.co/CycdYdXpMC #BCSM

— JAMA Oncology (@JAMAOnc) March 4, 2022